(GLOBE NEWSWIRE) -- (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Amit Munshi has been ...

Atopic dermatitis’ (AD) deeper complexities were exposed in 2025. Once seen mainly as a visible skin condition, AD is now widely recognized as a long-lasting inflammatory disease that affects sleep, ...

Once limited to nonspecific anti-inflammatory therapies, expanding treatment options for atopic dermatitis are allowing therapy to be individualized.

"Galderma’s Nemluvio shows itch reduction in 48 hours" was originally created and published by Clinical Trials Arena, a ...

Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview: Sanofi is running a global registry called “Atopic ...

JAK inhibitor treatment is not associated with stunted growth in children with common inflammatory diseases, according to a ...

InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval ...

Nektar Therapeutics may have a pipeline-in-a-drug with rezpegaldesleukin, has additional readouts ahead, and cash until 2027.

A new study from North Carolina State University found that neutrophils—white blood cells that are a key part of the immune ...

The future of dermatology is no longer just skin deep. This year’s American Academy of Dermatology (AAD) annual meeting was held March 7-11, 2025, in Orlando, FL, and it showcased the specialty’s ...

IL-31 is a neuroimmune cytokine that drives itch and other symptoms in both atopic dermatitis and prurigo nodularis. 3,4 These new findings reinforce the critical role of IL-31 pathway inhibition in ...

While Eczema and Dermatitis are skin conditions, they are non-contagious but are often triggered by irritants, allergens, dry ...